In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations

Nuclear Medicine and Biology

Volumn 37, Issue 1, 2010, Pages 3-8

  Kilbourn, Michael R ^a   Butch, Elizabeth R ^a   Desmond, Timothy ^a   Sherman, Phillip ^a   Harris, Paul E ^b   Frey, Kirk A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Methyl p tyrosine; Dopamine; Tetrabenazine; Tomography, emission computed; Vesicular monoamine transporter

Indexed keywords

BENSERAZIDE; CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; METHYLPHENIDATE; METIROSINE; RADIOLIGAND; VESICULAR MONOAMINE TRANSPORTER 2; CARBON; DRUG DERIVATIVE; SLC18A2 PROTEIN, RAT; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; CATECHOLAMINE DEPLETION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; MALE; NONHUMAN; RADIOASSAY; RAT; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; NEOSTRIATUM; PROTEIN BINDING;

ALPHA-METHYLTYROSINE; ANIMALS; CARBON RADIOISOTOPES; DOPAMINE; MALE; NEOSTRIATUM; PROTEIN BINDING; RATS; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 72449135242     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.08.013     Document Type: Article

References (31)

1. Frey K.A., Koeppe R.A., and Kilbourn M.R. Imaging the vesicular monoamine transporter. Advances in neurology (2001), Lippincott, Williams and Wilkins, Philadelphia 237-247
2. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61 (2003) 310-315
3. Bohnen N.I., Koeppe R.A., Meyer P., Ficaro E., Wernette K., Kilbourn M.R., et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 54 (2006) 1753-1759
4. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26 (2006) 1198-1212
5. De La Fuente-Fernandez R., Furtado S., Guttman M., Furukawa Y., Lee C.S., Calne D.B., et al. VMAT2 binding is elevated in DOPA-responsive dystonia: visualizing empty vesicles by PET. Synapse 49 (2003) 20-28
6. Gilman S., Koeppe R.A., Chervin R.D., Consens F.B., Little R., An H., et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 61 (2003) 29-33
7. 18F-FDG PET measures in differentiating dementias. J Nucl Med 46 (2005) 936-944
8. Martin W.R.W., Wieler M., Stoessl J., and Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 63 (2008) 388-394
9. Zubieta J.K., Taylor S.F., Huguelet P., Koeppe R.A., Kilbourn M.R., and Frey K.A. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49 (2001) 110-116
10. Kilbourn M.R., Frey K.A., Vander Borght T., and Sherman P.S. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 23 (1996) 467-471
11. Naudon L., Leroux-Nicollet I., and Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter. Neurosci Lett 173 (1994) 1-4
12. Vander Borght T.M., Kilbourn M.R., Desmond T.J., Kuhl D.E., and Frey K.A. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294 (1995) 577-583
13. Vilpoux C., Leroux-Nicollet I., Naudon L., Raisman-Vozari R., and Costentin J. Reserpine or chronic fluoxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharm 39 (2000) 1075-1082
14. Wilson J.M., and Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16 (1996) 3507-3510
15. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62 (2008) 873-876
16. De La Fuentes-Fernandez R., Sossi V., McCormick S., Shulzer M., Ruth T.J., and Stoessl A.J. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63 (2009) 713-716
17. 11C]DTBZ binding in awake rat brain. NeuroImage 41 Suppl. 2 (2008) T54
18. 11C]dihydrotetrabenazine. Appl Radiat Isot 24 (1997) 197-199
19. 3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol 331 (1997) 161-168
20. Kilbourn M.R. Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain. Nucl Med Biol 31 (2004) 591-595
21. Frey K., Kilbourn M., and Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334 (1997) 273-279
22. Widerlov E., and Lewander T. Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after α-methyl-p-tyrosine: time and dose-response relationships. Naunyn Schmiedebergs Arch Pharmacol 304 (1978) 111-123
23. Naudon L., Leroux-Nicollet I., Raisman-Vozari R., Botton D., and Costentin J. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse 21 (1995) 29-36
24. 11C]cocaine binding to decreases in synaptic dopamine. Synapse 20 (1995) 137-144
25. 11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 281 (1995) 141-149
26. 3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250 (1993) 261-266
27. 3H]WIN 35,428 to the central dopamine transporters. Synapse 23 (1996) 61-69
28. Buu N.T. Vesicular accumulation of dopamine following l-DOPA administration. Biochem Pharmacol 38 (1989) 1787-1792
29. Doshi P.S., and Edwards D.J. Effects of l-DOPA on dopamine and norepinephrine concentrations in rat brain assessed by gas chromatography. J Chromatogr 210 (1981) 505-551
30. Wachtel S.R., and Abercrombie E.D. l-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63 (1994) 108-117
31. --dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors and signaling systems. Pharmacol Ther 92 (2001) 21-55